High-Risk Stage II Colon Cancer: Not All Risks Are Created Equal

Annals of Surgical Oncology

Volumn 25, Issue 7, 2018, Pages 1980-1985

  Babcock, Blake D ^a   Aljehani, Mayada A ^a   Jabo, Brice ^a   Choi, Audrey H ^a   Morgan, John W ^a   Selleck, Matthew J ^a   Luca, Fabrizio ^a   Raskin, Elizabeth ^a   Reeves, Mark E ^a   Garberoglio, Carlos A ^a   Lum, Sharon S ^a   Senthil, Maheswari ^a  

^a LOMA LINDA UNIVERSITY HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; COLON ADENOCARCINOMA; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; LYMPH NODE; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PERINEURAL INVASION; TREATMENT OUTCOME; ADENOCARCINOMA; COLON TUMOR; FOLLOW UP; MORTALITY; PATHOLOGY; RISK FACTOR; SURVIVAL RATE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RISK FACTORS; SURVIVAL RATE;

EID: 85045757312     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-018-6484-8     Document Type: Article

References (21)

1. Andre T, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16.
2. Quasar Collaborative G, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–9.
3. Efficacy of adjuvant fluorouracil and folinic acid in b2 colon cancer. J Clin Oncol. 1999;17(5):1356–63.
4. Meyers BM, et al. Adjuvant systemic chemotherapy for stages II and III colon cancer after complete resection: a clinical practice guideline. Curr Oncol. 2016;23(6):418–24.
5. Casadaban L, et al. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer. Cancer. 2016;122(21):3277–87.
6. Sato H, et al. High-risk stage II colon cancer after curative resection. J Surg Oncol. 2011;104(1):45–52.
7. Artac M, et al. Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study. Tumori. 2014;100(2):143–8.
8. Benson AB 3rd, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408–19.
9. Kumar A. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer. 2015;121(4):527–34.
10. Park JS, et al. High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. J Cancer Res Clin Oncol. 2016;142(9):2051–9.
11. Weiss, JM, et al. Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data. Ann Surg Oncol. 2014;21(6):1781–91.
12. National Comprehensive Cancer Network. NCCN Guidelines Colon Cancer (Version 2.2017). National Comprehensive Cancer Network; https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
13. Quah HM, et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum. 2008;51(5):503–7.
14. Tsikitis VL, et al. Predictors of recurrence free survival for patients with stage II and III colon cancer. BMC Cancer. 2014;14:336.
15. Fritz AG. International classification of diseases for oncology: ICD-O. 3rd edn. First revision edn. 2013, Geneva: World Health Organization. viii, 242 pages.
16. Verhoeff SR, et al. Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer. Int J Cancer. 2016;139(1):187–93.
17. Le Voyer TE, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol. 2003;21(15):2912–9.
18. Swanson RS, et al. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol. 2003;10(1):65–71.
19. Chang GJ, et al. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst. 2007;99(6):433–41.
20. Santos C, et al. Clinicopathological risk factors of Stage II colon cancer: results of a prospective study. Colorectal Dis. 2013;15(4):414–22.
21. Schippinger W, et al. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer. 2007;97(8):1021–7.